Abstract Placebo and placebo effect are important issues related to the drug therapy for clinical and scientific meanings. The rates of placebo may get as many as 50% for analgesic drugs in headache. The high answer to placebo brings questions on pathophysiology of headache. Answers may offer a new strategy in the implementation of trials and new insight in neurophysiology of headache. Current knowledge on placebo and placebo effect will be analysed and discussed looking for new direction in headache field.

Key words Placebo • Headache • Migraine • Treatment • Drug therapy

Introduction

The placebo effect per se is evidence of the reciprocal influence of the mind and brain. Pain is not related to chemical and neural transmission only: desire and expectancy of pain relief, as cultural and individual factors, are direct components of pain and pain reduction.

A primary role of medicine is to diagnose and treat a patient’s illness by treating the body without excluding the person who is experiencing the illness [1] with his/her mind. The dualistic perspective shows traces of Cartesian dualism: a human being consists of two incompatible substance, res cogitans and res extensa, the mind and the body that are completely separate and distinct. This point of view is incomplete because body and mind, biology and psychology, nature and culture are not alternative viewpoints. Mind and body are integrated by neural and biochemical circuits that communicate with one another. A full understanding of the human brain requires an integrated perspective, where mind and body (reciprocally related) fully interact with the physical and social environment [2].

However, several questions remain unanswered: How do the biological processes of the brain give rise to mental events, and how, in turn, do social factors modulate the biological structure of the brain? To what degree is this biological process determined by genetic and develop-
mental factors? To what degree is it environmentally or socially determined? [3]. All mental processes are biological, and therefore any alteration in these processes is necessarily organic. Learning and experience have a critical role in the regulation of gene expression. Each gene has a double function: a template function that guarantees the fidelity of replication and a transcriptional function that is responsive to environmental factors [3]. Understanding the role and mechanisms of placebo might improve the implementation of trials and extend our knowledge in the field of headache.

Placebo effect

There is no unique definition of “placebo”, from the Latin “I shall please”. Gotzsche (1994) said that “the placebo concept as presently used cannot be defined in a logically consistent way and leads to contradictions” [4]. A placebo is both a pharmacologically inert substance and “any effect attributable to a pill, potion, or procedure, but not to its pharmacodynamic or specific properties” [5].

The tradition of placebo research goes back to the 1950s. In 1955, Henry K. Beecher, with his famous article “The Powerful Placebo”, quantified the effects of placebo in a variety of diseases. By collecting data from 15 different studies, he showed that the symptoms of 35% of 1,082 patients were relieved by placebo alone [6].

There are three general reasons for clinical improvement: the specific effect of the drug or other treatment being tested, the effect due to the natural history of the disease, or the placebo effect [7]. It should also be stressed that there might be many factors that may create false placebo effects such as the natural course of a disease (e.g. spontaneous improvement, fluctuation of symptoms, regression to the mean, habituation), additional treatment (e.g. diet for irritable colon treatment), or patient bias (e.g. answer of politeness and experimental subordination) [8].

There are different points of view about the use of placebo: some think that the use of placebo in clinical trials means only that some patients take medications that are without efficacy; for others the use of placebo is often the only way to establish the efficacy of new drugs [9].

In trials using placebo, several variables should be considered, such as the characteristics of placebo (appearance, volume, number of intake and route of administration), the effects of the ingredients used as placebo and the ethical problems [10].

Today, the use of placebo-controlled trials in medical settings is required in order to assess both the efficacy and safety of drugs and to determine the extent of the therapeutical effect.

An absolute ethical condition in clinical placebo-controlled trials is that the patients (adults or children) are not harmed or put at significant risk during the research. There are reports in the literature of the nocebo phenomenon, from the Latin “I will harm”. The nocebo phenomenon refers to symptoms or physiological changes that follow the employment of an inert, chemically inactive substance that the patient believes to be an active drug [11]. Placebo therapy is not a “non-therapy”. The efficacy of placebo is well known, but less well known is the fact that placebo medications can produce adverse reactions [12]. Benson asserted that there are three components that make up the placebo and nocebo effect: the first is the belief or expectancy harboured by the patient; the second is the belief or expectancy on the part of the physician; the third is the belief or expectancy that is engendered by the relationship between the two [13].

It is important to differentiate between the “placebo effect” and “non-specific effect” of drugs, because several dimensions (psychological, cognitive, affective motivational) can modulate a personal response to certain situations or stimuli. Expectancy of drug efficacy and individual differences in suggestibility were found to contribute significantly to the magnitude of placebo analgesia [14]. Personality factors, mood disorders, anxiety and emotional distress can be associated with placebo effects [15]. Subjects with depression often have a pessimistic and negative concept of events and an external locus of control; an anxious person can experience somatization and view the placebo as a threat, thereby amplifying the negative symptoms (tachycardia, dyspnoea, sweating) [15]. The placebo response embraces a variety of these non-specific factors which will combine in many cases to produce an improvement; this is true in all fields of medicine but the effects can be particularly potent in psychiatry [16]. Psychiatric disorders have a high placebo response: endogenous-type depression and neurotic or reactive depression have placebo response rates around 30% and 70%, respectively [17], generalized anxiety disorder varies widely between 18% and 67% [18], panic attack between 20% and 134% with a median of 56% [19], and social phobia between 7% and 43% [20].

The placebo effects are not merely an aspecific response; in studies on pain and analgesia, the neurophysiological mechanisms of the placebo effect were investigated. Some aspects of placebo analgesia are dependent on the endogenous opioid system. Expectation cues and/or morphine conditioning produced placebo responses that were completely antagonized by naloxone; by contrast, non-opioid conditioning alone produced placebo responses that were naloxone-insensitive. Therefore, placebo analgesia could be activated by the opioid or non-opioid system: the expectation may also trigger endogenous opioids [21].
Microinjection of opioid directly into the nucleus accumbens was shown to induce antinociception, and microinjection of the opioid antagonist naloxone into the nucleus accumbens was seen to attenuate the antinociceptive effect. The nucleus accumbens, an important component of the mesolimbic dopaminergic reward system, plays a role in pain modulation [22].

Placebo analgesia is associated with patterns of cerebral blood-flow activation (particularly the rostral anterior cingulated cortex) similar to those seen after injection of an active opioid [23].

Positron emission tomography performed on 17 patients with unipolar depression after 6 weeks of fluoxetine or placebo (double-blind trial) showed the same biochemical changes in different cerebral regions for both treatments [24]. Roughly 50–75% of the efficacy of antidepressant medications represents the placebo effect. In a double-blind placebo-controlled study, 38% of the patients with depression were placebo responders (vs. 52%); placebo responders showed a significant increase in prefrontal cordance [25].

The use of placebo is particularly difficult when concerning children: development markedly influences the absorption, distribution, metabolism and excretion of drugs. A rational drug therapy in children and adolescents requires individualizing treatment as well as recognizing individual (comorbidity, concurrent medications), developmental (pharmacodynamic, pharmacokinetic) and environmental factors (diet, environmental contaminants) that could influence drug disposition and response.

**Placebo and headache**

Placebo-controlled trials are necessary when the studied population has a high placebo response rate with frequent spontaneous remissions and existing therapies are only partly effective: all these criteria are fulfilled by headache [26].

A study evaluating the placebo response in acute treatment of migraine without or with aura and episodic tension-type headache showed pain relief after placebo administration in all groups (50%, 23.3% and 26.7%, respectively) [27]. In adults, 2 h after treatment, positive headache response to placebo ranges between 7% and 50% of migraineurs (average response rate of 30%) and pain-free response to placebo ranges between 7% and 17% (average response of 9%) [28]. In cluster headache, the placebo response varies from 7% to 42% (acute therapy) and from 14% to 43% (prophylactic treatment) [29].

The placebo effect for migraine prevention in children has been estimated to be as high as 40%–50% [30]. High responses to placebo are present in trials on treatment with triptans; on adults, trials on triptans record a response to placebo (combined data) ranging from 18% to 35% [31]. Trials on triptans showed a higher placebo effect in children and adolescents than in adults: in children, the response to placebo ranges from 14% to 40% and in adolescents from 25% to 61%.

This finding may stimulate intriguing questions on (a) the diversity between adults and children and/or adolescents in the explanation of such different responses to drugs, (b) which factors are involved, and (c) the way of limiting likely shortcomings in findings. In a review of 109 double-blind, placebo-controlled drug trials, an average of 19% of patients on placebo reported adverse side effects; headache led the list at 7% [15]. Reuter et al. [32] analysed the adverse events of placebo in acute and preventive randomized, double-blind, placebo-controlled studies for migraine treatment. From 10% to 30% of subjects reported adverse events after placebo, such as (most common) nausea, phono- and photophobia [32].

On one hand, the high response rates to placebo show the critical importance of realizing placebo-controlled trials in the field of headache research. On the other, the wide variability in percentage range stresses the probable differences in methodology that should be better controlled in the implementation of trials in order to yield more accurate findings. For example, the high psychiatric comorbidity shown by headache sufferers, both adult and pediatric patients [33–35], should be considered in the trials on headache, because of the above-mentioned high response of psychiatric patients to placebo.

It is noteworthy that placebo induces biochemical changes, not only a response “by suggestion”. A better understanding of such changes in the central nervous system may contribute to the comprehension of the pathophysiology of headache. Toward this aim, we should try gain a better understanding of which factors distinguish placebo responders, so as to improve the implementation of trials on headache and avoid bias related to personality factors of proband subjects.

A better understanding of placebo mechanisms could also show a likely common aetiology of both disorders, such as the hypothesized implication of the serotonergic system in both migraine and depression [36–37].

To date, we may only formulate questions on the involvement of placebo and the consequences for the pathophysiology of headache. Answers may offer a new strategy in the implementation of trials and new insight on the pathophysiology of headache.
References

1. Switankowsky I (2000) Dualism and its importance for medicine. Theor Med 21:567–580
2. Damasio AR (2001) Descartes’ error revisited. J Hist Neurosci 10:192–194
3. Kandel ER (1998) A new intellectual framework for psychiatry. Am J Psychiatry 155:457–469
4. Gotzsche PC (1994) Is there logic in the placebo? Lancet 344:925–926
5. Wolf S (1959) The pharmacology of placebo. Pharmacol Rev 11:689–704
6. Beecher HK (1955) The powerful placebo. J Am Med Assoc 159:1602–1606
7. Thompson WG (2000) Placebos: a review of the placebo response. Am J Gastroenterol 95:1637–1643
8. Kienle GS, Kiene H (1997) The powerful placebo: Fact or Fiction? J Clin Epidemiol 50:1311–1318
9. Young SN, Annable L (2002) The ethics of placebo in clinical psychopharmacology: the urgent need for consistent regulation. J Psychiatry Neurosci 27:319–321
10. Emilien G, Maloteaux JM, Seghers A, Charles G (1998) Use of a placebo in clinical trials. Eur Psychiatry 13:254–263
11. Barsky AJ, Saintfort R, Rogers MP (2002) Nonspecific medication side effects and the nocebo phenomenon. JAMA 287:622–627
12. Weithrauch TR (2000) Placebo effects and adverse effects in clinical trials. Med Klin 95:23–30
13. Benson H (1997) The nocebo effect: history and Physiology. Prev Med 26:612–615
14. De Pascalis V, Chiaradia C, Carotenuto E (2002) The contribution of suggestibility and expectation to placebo analgesia phenomenon in an experimental setting. Pain 96:393–402
15. Evans RW, Rogers MP (2003) Headache and the nocebo effect. Headache 43:1113–1115
16. Montgomery SA (1999) Alternatives to placebo-controlled trials in psychiatry. Eur Neuropsychopharmacol 9:265–269
17. Brown WA (1998) Predictors of placebo response in depression. Psychopharmacol Bull 24:14–17
18. Loebel AD, Hyde TS, Dunner DL (1986) Early placebo response in anxious patients. J Clin Psychiatry 47:230–232
19. Merz WA (1994) Placebo response in panic disorder. A review. Eur Psychiatry 9:123–127
20. Versiani M, Nardi AE, Mundim FD, Alves AB, Liebowitz MR, Amrein R (1992) Pharmacotherapy of social phobia: a controlled study with moclobemide and phenelzine. Br J Psychiatry 161:353–360
21. Amanzio M, Benedetti F (1999) Neuropharmacological dissection of placebo analgesia: expectation-activated opioid system versus conditioning-activated specific subsystems. J Neurosci 1:484–494
22. Lewis RW, Aley KO, Levine JD (1999) Pain-induced analgesia mediated by mesolimbic reward circuits. J Neurosci 19:7175–7181
23. Petrovic P, Kalso E, Petersson KM, Ingvar M (2002) Placebo and opioid analgesia-imaging a shared neuronal network. Science 295:1737–1740
24. Mayberg HS, Silva JA, Brannan SK, Tekell JL, Makris N, McGinnis S, Jerabek PA (2002) The functional neuroanatomy of the placebo effect. Am J Psychiatry 159:728–737
25. Leuchter AF, Cook IA, Witte EA, Morgan M, Abrams M (2002) Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry 159:122–129
26. Linde M, May A, Limroth V, Dahlöf C (2003) Ethical aspects of placebo in migraine research. Cephalalgia 23:491–495
27. Bigal ME, Bigal JO, Bordini CA, Speciai JG (2001) Evaluation of placebo use in migraine without aura, migraine with aura and episodic tension-type headache acute attacks. Arq Neuropsiquiatr 59:552–558
28. Bendsten L, Mattsson P, Zwart J-A, Lipton RB (2003) Placebo response in clinical randomized trials of analgesics in migraine. Cephalalgia 23:487–490
29. Nilsson Remahl AI, Laudon Meyer E, Cordonnier C, Goadsby PJ (2003) Placebo response in cluster headache trials: a review. Cephalalgia 23:504–510
30. Wasiowski WW (2001) Preventive therapy in pediatric migraine. J Child Neurol 16:71–78
31. Gavel MJ, Worthington I, Maggsano A (2001) A systematic review of the use of triptans in acute migraine. Can J Neurol Sci 28:30–41
32. Reuter U, Sanchez del Rio M, Carpay JA, Boes CJ, Silberstein SD (2003) Placebo adverse events in headache trials: headache as an adverse event of placebo. Cephalalgia 23:496–507
33. Merikangas KR (1994) Psychopathology and headache syndromes in the community. Headache 34:S17–S26
34. Guidetti V, Galli F, Fabrizi P, Napoli L, Giamantoni AS, Bruni O, Trillo S (1998) Headache and psychiatric comorbidity: clinical outcomes and outcome in a 8-year follow-up study, Cephalalgia 7:455–462
35. Egger HL, Angold A, Costello J (1998) Headache and psychiatric comorbidity: clinical aspects and outcome in an 8-year follow-up study, Cephalalgia 7:455–462
36. Egger HL, Angold A, Costello J (1998) Headache and psychopathology in children and adolescents. J Am Acad Child Adolesc Psychiatry 37:951–958
37. Glovcr V, Jarman J, Sandler M (1993) Migraine and depression: biological aspects. J Psychiat Res 2:223–231
38. Silberstein SD (1994) Serotonin (5-HT) and migraine. Headache 34:408–417